Neurocrine Biosciences, Inc. (NBIX)
148.06
+1.04
(+0.71%)
USD |
NASDAQ |
May 07, 11:57
Neurocrine Biosciences Cash from Investing (Quarterly) : -506.20M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Soleno Therapeutics, Inc. | -125.36M |
| Glaukos Corp. | 10.50M |
| Edgewise Therapeutics, Inc. | 49.76M |
| Nuvalent, Inc. | -280.94M |
| Biogen, Inc. | -209.50M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 145.80M |
| Cash from Financing (Quarterly) | -86.10M |
| Free Cash Flow | 831.30M |
| Free Cash Flow Per Share (Quarterly) | 1.322 |
| Free Cash Flow to Equity (Quarterly) | 201.80M |
| Free Cash Flow to Firm (Quarterly) | 136.70M |
| Free Cash Flow Yield | 5.47% |